13856

    526953

    VENUSREM

    No Data Available

    Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

    VENUS REMEDIES LIMITED Share Price Today

    VENUS REMEDIES LIMITED is currently trading at ₹1543.8, down by ₹18.89 from the previous close. The stock touched an intraday high of ₹1562.70 and a low of ₹1521.00 during the latest trading session. Over the past one year, VENUS REMEDIES LIMITED has delivered a return of 199.44%, while the stock has declined 8.38% in the last one month.

    VENUS REMEDIES LIMITED performance

    Today’s low Today’s high
    ₹ 1521.00 ₹ 1562.70
    ₹ 1531.00
    52 week low 52 week high
    ₹ 424.00 ₹ 2044.30
    ₹ 1531.00
    Open Price ₹ 1562.70
    Prev. Close ₹ 1562.70
    Volume (Shares) 12180.00
    Total traded value ₹ 186.47
    Upper Circuit ₹ 1630.30
    Lower Circuit ₹ 1475.10
    info

    Investment Returns

    Over 1 Month -8.38% Over 3 Months 60.46% Over 6 Months 100.94% Over 1 Year 199.44%
    Smart Investing Starts here ! Trade Smart with Fast Execution & Zero Account Opening Fees Invest Now

    VENUS REMEDIES LIMITED fundamentals


    • Market cap (Cr) 2,065.60
    • P/E Ratio (TTM) 18.46
    • Beta 0.85
    • Book Value / share 515.91
    • Return on equity 8.10%
    • EPS (TTM) 84.64
    • Dividend yield 0.64%
    • Net profit/quarter (Cr) 25.53
    info icon alternate text
    • Market cap (Cr) 2,070.40
    • P/E Ratio (TTM) 18.46
    • Beta 0.79
    • Book Value / share 515.91
    • Return on equity 8.10%
    • EPS (TTM) 84.64
    • Dividend yield 0.64%
    • Net profit/quarter (Cr) 25.53
    info icon alternate text

    VENUS REMEDIES LIMITED Financials

    Open financial information
    Revenue
    Net income
    Particulars JUN 2026 (Values in Cr)
    Revenue 178.80
    Operating Expense 148.75
    Net Profit 25.53
    Net Profit Margin (%) 14.27
    Earnings Per Share (EPS) 19.10
    EBITDA 39.11
    Effective Tax Rate (%) 21.68
    Particulars MAR 2026 (Values in Cr)
    Revenue 259.01
    Operating Expense 206.08
    Net Profit 43.45
    Net Profit Margin (%) 16.77
    Earnings Per Share (EPS) 32.51
    EBITDA 64.08
    Effective Tax Rate (%) 24.52
    Particulars DEC 2025 (Values in Cr)
    Revenue 179.95
    Operating Expense 149.55
    Net Profit 24.92
    Net Profit Margin (%) 13.84
    Earnings Per Share (EPS) 18.64
    EBITDA 39.13
    Effective Tax Rate (%) 24.04
    Particulars SEP 2025 (Values in Cr)
    Revenue 192.65
    Operating Expense 168.73
    Net Profit 19.24
    Net Profit Margin (%) 9.98
    Earnings Per Share (EPS) 14.40
    EBITDA 31.52
    Effective Tax Rate (%) 24.84
    Particulars JUN 2025 (Values in Cr)
    Revenue 137.13
    Operating Expense 125.15
    Net Profit 11.69
    Net Profit Margin (%) 8.52
    Earnings Per Share (EPS) 8.75
    EBITDA 20.65
    Effective Tax Rate (%) 20.47
    Particulars MAR 2026 (Values in Cr)
    Revenue 768.73
    Operating Expense 649.50
    Net Profit 99.31
    Net Profit Margin (%) 12.91
    Earnings Per Share (EPS) 74.29
    EBITDA 155.37
    Effective Tax Rate (%) 24.00
    Particulars MAR 2025 (Values in Cr)
    Revenue 644.47
    Operating Expense 591.09
    Net Profit 52.55
    Net Profit Margin (%) 8.15
    Earnings Per Share (EPS) 39.32
    EBITDA 100.68
    Effective Tax Rate (%) 33.53
    Particulars MAR 2024 (Values in Cr)
    Revenue 575.21
    Operating Expense 539.88
    Net Profit 30.50
    Net Profit Margin (%) 5.30
    Earnings Per Share (EPS) 22.82
    EBITDA 72.20
    Effective Tax Rate (%) 34.61
    Particulars MAR 2023 (Values in Cr)
    Revenue 537.66
    Operating Expense 507.50
    Net Profit 28.96
    Net Profit Margin (%) 5.38
    Earnings Per Share (EPS) 21.67
    EBITDA 71.70
    Effective Tax Rate (%) 28.19
    Particulars MAR 2022 (Values in Cr)
    Revenue 576.71
    Operating Expense 540.47
    Net Profit 48.99
    Net Profit Margin (%) 8.49
    Earnings Per Share (EPS) 37.12
    EBITDA 77.25
    Effective Tax Rate (%) -9.67
    Particulars MAR 2025 (Values in Cr)
    Book Value / Share 419.65
    ROE % 7.16
    ROCE % 10.93
    Total Debt to Total Equity 0.04
    EBITDA Margin 12.79
    Particulars MAR 2024 (Values in Cr)
    Book Value / Share 364.74
    ROE % 6.01
    ROCE % 8.52
    Total Debt to Total Equity 0.09
    EBITDA Margin 11.83
    Particulars MAR 2023 (Values in Cr)
    Book Value / Share 344.38
    ROE % 5.90
    ROCE % 7.59
    Total Debt to Total Equity 0.09
    EBITDA Margin 12.66
    Particulars MAR 2022 (Values in Cr)
    Book Value / Share 329.50
    ROE % 9.69
    ROCE % 7.76
    Total Debt to Total Equity 0.11
    EBITDA Margin 11.73
    Particulars MAR 2021 (Values in Cr)
    Book Value / Share 313.18
    ROE % 10.59
    ROCE % 7.55
    Total Debt to Total Equity 0.38
    EBITDA Margin 13.39
    Particulars MAR 2025 (Values in Cr)
    Book Value / Share 441.01
    ROE % 8.10
    ROCE % 11.75
    Total Debt to Total Equity 0.04
    EBITDA Margin 13.94
    Particulars MAR 2024 (Values in Cr)
    Book Value / Share 380.48
    ROE % 6.18
    ROCE % 8.61
    Total Debt to Total Equity 0.08
    EBITDA Margin 12.55
    Particulars MAR 2023 (Values in Cr)
    Book Value / Share 357.63
    ROE % 6.24
    ROCE % 7.89
    Total Debt to Total Equity 0.08
    EBITDA Margin 13.34
    Particulars MAR 2022 (Values in Cr)
    Book Value / Share 336.21
    ROE % 11.53
    ROCE % 9.39
    Total Debt to Total Equity 0.10
    EBITDA Margin 13.39
    Particulars MAR 2021 (Values in Cr)
    Book Value / Share 313.10
    ROE % 8.42
    ROCE % 6.00
    Total Debt to Total Equity 0.36
    EBITDA Margin 12.56
    Particulars MAR 2025 (Values in Cr)
    Cash & Short Term Investments 80.10
    Total Assets 715.72
    Total Liabilities 715.72
    Total Equity 560.94
    Share Outstanding 1
    Price to Book Ratio 0.68
    Return on Assets (%) 6.33
    Return on Capital (%) 8.05
    Particulars MAR 2024 (Values in Cr)
    Cash & Short Term Investments 68.09
    Total Assets 626.82
    Total Liabilities 626.82
    Total Equity 487.55
    Share Outstanding 1
    Price to Book Ratio 0.86
    Return on Assets (%) 4.54
    Return on Capital (%) 5.39
    Particulars MAR 2023 (Values in Cr)
    Cash & Short Term Investments 54.44
    Total Assets 601.08
    Total Liabilities 601.08
    Total Equity 460.33
    Share Outstanding 1
    Price to Book Ratio 0.45
    Return on Assets (%) 4.41
    Return on Capital (%) 5.29
    Particulars MAR 2022 (Values in Cr)
    Cash & Short Term Investments 50.39
    Total Assets 579.81
    Total Liabilities 579.81
    Total Equity 440.44
    Share Outstanding 1
    Price to Book Ratio 0.80
    Return on Assets (%) 7.02
    Return on Capital (%) 8.43
    Particulars MAR 2021 (Values in Cr)
    Cash & Short Term Investments 31.41
    Total Assets 555.85
    Total Liabilities 555.85
    Total Equity 400.28
    Share Outstanding 1
    Price to Book Ratio 0.88
    Return on Assets (%) 11.11
    Return on Capital (%) 13.68
    Particulars MAR 2025 (Values in Cr)
    Cash & Short Term Investments 77.98
    Total Assets 713.21
    Total Liabilities 713.21
    Total Equity 589.49
    Share Outstanding 1
    Price to Book Ratio 0.68
    Return on Assets (%) 7.36
    Return on Capital (%) 8.92
    Particulars MAR 2024 (Values in Cr)
    Cash & Short Term Investments 67.64
    Total Assets 641.26
    Total Liabilities 641.26
    Total Equity 508.59
    Share Outstanding 1
    Price to Book Ratio 0.86
    Return on Assets (%) 4.75
    Return on Capital (%) 5.57
    Particulars MAR 2023 (Values in Cr)
    Cash & Short Term Investments 53.30
    Total Assets 608.89
    Total Liabilities 608.89
    Total Equity 478.04
    Share Outstanding 1
    Price to Book Ratio 0.45
    Return on Assets (%) 4.75
    Return on Capital (%) 5.61
    Particulars MAR 2022 (Values in Cr)
    Cash & Short Term Investments 49.96
    Total Assets 578.66
    Total Liabilities 578.66
    Total Equity 449.41
    Share Outstanding 1
    Price to Book Ratio 0.80
    Return on Assets (%) 8.46
    Return on Capital (%) 10.04
    Particulars MAR 2021 (Values in Cr)
    Cash & Short Term Investments 30.24
    Total Assets 546.81
    Total Liabilities 546.81
    Total Equity 400.18
    Share Outstanding 1
    Price to Book Ratio 0.88
    Return on Assets (%) 9.92
    Return on Capital (%) 12.12
    Particulars MAR 2025 (Values in Cr)
    Net Income 61.87
    Cash from Operations 101.36
    Cash from Investing -76.24
    Cash from Financing -1.01
    Net change in Cash 9.17
    Free Cash Flow 110.99
    Particulars MAR 2024 (Values in Cr)
    Net Income 44.64
    Cash from Operations 52.76
    Cash from Investing -7.20
    Cash from Financing -1.08
    Net change in Cash 28.99
    Free Cash Flow 62.08
    Particulars MAR 2023 (Values in Cr)
    Net Income 37.93
    Cash from Operations 36.62
    Cash from Investing -50.82
    Cash from Financing -0.56
    Net change in Cash -14.76
    Free Cash Flow 44.44
    Particulars MAR 2022 (Values in Cr)
    Net Income 36.40
    Cash from Operations 41.10
    Cash from Investing -16.72
    Cash from Financing -9.47
    Net change in Cash 14.89
    Free Cash Flow 41.10
    Particulars MAR 2021 (Values in Cr)
    Net Income 25.11
    Cash from Operations 108.39
    Cash from Investing 56.49
    Cash from Financing -162.24
    Net change in Cash 26.08
    Free Cash Flow 108.39
    Particulars MAR 2025 (Values in Cr)
    Net Income 69.16
    Cash from Operations 98.02
    Cash from Investing -76.20
    Cash from Financing 0.00
    Net change in Cash 6.89
    Free Cash Flow 107.60
    Particulars MAR 2024 (Values in Cr)
    Net Income 46.65
    Cash from Operations 50.86
    Cash from Investing -6.94
    Cash from Financing 0.00
    Net change in Cash 28.43
    Free Cash Flow 59.91
    Particulars MAR 2023 (Values in Cr)
    Net Income 40.32
    Cash from Operations 28.05
    Cash from Investing -50.81
    Cash from Financing 0.00
    Net change in Cash -22.75
    Free Cash Flow 35.85
    Particulars MAR 2022 (Values in Cr)
    Net Income 44.67
    Cash from Operations 41.00
    Cash from Investing -16.75
    Cash from Financing -9.12
    Net change in Cash 15.12
    Free Cash Flow 54.68
    Particulars MAR 2021 (Values in Cr)
    Net Income 17.61
    Cash from Operations 108.89
    Cash from Investing 55.98
    Cash from Financing -161.87
    Net change in Cash 26.44
    Free Cash Flow 108.89
    Company Name Price P/E P/B Market Cap 52 Week Low 52 Week High
    AMBALAL SARABHAI ENT L 43.10 17.88 2.08 330.29 23.12 45.50
    BLISS GVS PHARMA LTD. 505.05 40.66 4.49 5365.85 118.35 552.90
    CIPLA LTD 1450.00 32.73 3.40 117137.57 1165.55 1672.20
    FERMENTA BIOTECH LIMITED 551.65 25.80 3.99 1623.56 256.40 564.50
    Company Name Price P/E P/B Market Cap 52 Week Low 52 Week High
    AMBALAL SARABHAI ENT L 43.10 30.14 5.55 330.29 23.12 45.50
    AMRUTAJAN HEALTH LTD 525.20 23.54 4.10 1518.39 490.00 789.95
    ASTRAZENECA PHARMA IND LT 8091.60 105.74 23.17 20229.00 7630.00 9850.00
    BLISS GVS PHARMA LTD. 505.05 54.66 4.64 5365.85 118.35 552.90

    VENUS REMEDIES LIMITED shareholding pattern

    Holding
    54.43%
    41.75%
    2.91%
    0.88%
    Name Shares Category
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)

    News

    Left Arrow
    Right Arrow

    VENUS REMEDIES LIMITED Technicals Summary

    1545.30 -1.11 redarrow
    red-green-graph indicator
    12 Bearish
    4 Bullish
    • 5 Days 1559.30
    • 26 Days 1633.00
    • 10 Days 1584.90
    • 50 Days 1572.30
    • 12 Days 1596.00
    • 100 Days 1378.10
    • 20 Days 1627.00
    • 200 Days 1109.70
    1528.43 PIVOT
    First Support 1482.07 First Resistance 1570.67 Second Support 1439.83 Second Resistance 1617.03 Third Support 1393.47 Third Resistance 1659.27
    RSI 40.79 ADX 43.12 MACD -36.52 Williams % R -84.75 Commodity Channel Index (CCI) -104.23
    Date 2025-12-01 Week 79614.00 Same Day 85648.00 Month 83664.00
    1 Year 0.85 3 Year 0.83
    Over 1 Month
    -8.38% down
    Over 1 Year
    199.44% down
    Over 3 Months
    60.46% down
    Over 3 Years
    82.20% down
    Over 6 Months
    100.94% down
    Over 5 Years
    24.70% down

    VENUS REMEDIES LIMITED Corporate Actions

    Dividend date Dividend amount Dividend type Record date Instrument type
    07 Aug 2026 10.0 Final 07 Aug 2026 Equity shares
    23 Sep 2013 3.0 Final 25 Sep 2013 Equity shares
    20 Sep 2012 3.0 Final 24 Sep 2012 Equity shares
    22 Sep 2011 3.0 Final 25 Sep 2011 Equity shares
    23 Sep 2010 3.0 Final 25 Sep 2010 Equity shares
    17 Sep 2009 3.0 Final 20 Sep 2009 Equity shares
    12 Sep 2008 4.0 Final 16 Sep 2008 Equity shares
    18 Sep 2007 3.0 Final 20 Sep 2007 Equity shares
    Dividend date Dividend amount Dividend type Record date Instrument type
    07 Aug 2026 10.0 Final 07 Aug 2026 Equity shares
    23 Sep 2013 3.0 Final 25 Sep 2013 Equity shares
    20 Sep 2012 3.0 Final 24 Sep 2012 Equity shares
    22 Sep 2011 3.0 Final 25 Sep 2011 Equity shares
    23 Sep 2010 3.0 Final 25 Sep 2010 Equity shares
    17 Sep 2009 3.0 Final 20 Sep 2009 Equity shares
    12 Sep 2008 4.0 Final 16 Sep 2008 Equity shares
    18 Sep 2007 3.0 Final 20 Sep 2007 Equity shares

    Top Gainers

    Top Losers

    Trade stocks with ease

    Sign-in to trade with your demat account, or set up a new demat account for free

    Board Of Directors

    Similar stocks

    Frequently Asked Questions

    What is the Current Share Price of Venus Remedies Ltd?

    Answer Field

    Venus Remedies Ltd share price is for NSE ₹ 1,543.80 & for BSE ₹ 1,548.00 as on Aug 07 2026 12:53 PM.

    What is the Market Cap of Venus Remedies Ltd Share?

    Answer Field

    The market cap of Venus Remedies Ltd for NSE ₹ 0.00 & for BSE ₹ 0.00 as on Aug 07 2026 12:53 PM.

    What is the 52 Week High and Low of Venus Remedies Ltd?

    Answer Field

    The 52 Week High and Low of Venus Remedies Ltd for NSE is ₹ 2,044.30 and ₹ 424.00 and for BSE is ₹ 2,043.15 and ₹ 423.70.

    What is 1 year return for Venus Remedies Ltd?

    Answer Field

    The 1 year returns on the stock has been 213.22%.

    What is the P/E Ratio of Venus Remedies Ltd Share?

    Answer Field

    As on Aug 07 2026 12:53 PM the price-to-earnings (PE) ratio for Venus Remedies Ltd share is 18.46.

    What is the PB ratio of Venus Remedies Ltd Share?

    Answer Field

    As on Aug 07 2026 12:53 PM, the price-to-book (PB) ratio for Venus Remedies Ltd share is 515.91.

    How to Buy Venus Remedies Ltd Share?

    Answer Field

    You can trade in Venus Remedies Ltd shares with Bajaj Broking by opening a demat account.

    How to Buy Venus Remedies Ltd Share on Bajaj Broking App?

    Answer Field

    To buy Venus Remedies Ltd shares on the Bajaj Broking app, follow these steps:

    1. Login to the Bajaj Broking App

    2. Click on the Search Icon

    3. Search “Venus Remedies Ltd”

    4. Click on the BUY icon

    5. Place a buy order specifying the desired quantity of shares.

    6. Click BUY again to complete the purchase

    No results found

    close-img
    Authorise with OTP
    Enter the 4-Digit OTP sent to
    edit
    OTP expires in 00:59

    Open Your Free Demat Account

    Enjoy low brokerage on delivery trades

    +91

    |

    Open Your Free Demat Account

    Enjoy low brokerage on delivery trades

    +91

    |